Primary Small Cell Carcinoma of The Esophagus – An Eight Year Retrospective Study

Vasudevan, Geetha; Rao, Anjali; Kudva, Ranjini; Valliathan, Manna; Mathew, Mary; Rao, Lakshmi

doi:10.7860/jcdr/2015/12464.5927

Cited by 11 publications

(10 citation statements)

References 13 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Esophagoscopic biopsy is the most frequently used method for preoperative diagnosis. Most scholars 7,15,16 support the idea that SCCE arises from pluripotent stem cells of the endoderm, which differentiate into adenocarcinoma, squamous cell carcinoma, or SCC. The coexistence of SCCE with squamous cell carcinoma and/or adenocarcinoma in the same carcinoma is evidence for this viewpoint.…”

Section: Discussionmentioning

confidence: 99%

Treatment Strategies and Prognostic Factors of Limited-Stage Primary Small Cell Carcinoma of the Esophagus

Liu

et al. 2017

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Treatment Strategies and Prognostic Factors of Limited-Stage Primary Small Cell Carcinoma of the Esophagus

Liu

et al. 2017

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

“…Esophageal NENs are reported to constitute less than 1% of all esophageal cancers [ 16 ]. Several smaller studies have reported incidence of NENs to be 0.05–7.6% of all esophageal cancers [ 5 – 7 , 11 – 13 , 16 – 18 , 20 ]. In our study, 0.03% of all esophageal cancers were esophageal pure NENs.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological Profile of Pure Neuroendocrine Neoplasms of the Esophagus: A South Indian Center Experience

Kanakasetty

Dasappa

Lakshmaiah

et al. 2016

Journal of Oncology

View full text Add to dashboard Cite

Purpose. Neuroendocrine neoplasms (NENs) of the esophagus are very uncommon with only a few studies published worldwide. Studies on clinical profile, management, and outcomes are very uncommon. Methods. We report the largest single institution retrospective review of 43 patients of pure esophageal NENs out of our registry of gastrointestinal neuroendocrine tumors treated between 2005 and 2014. Data on the incidence, tumor location, clinical symptoms, stage at presentation, grading, treatment protocol, and treatment outcomes was collected and analyzed. Results. Among 1293 cases of esophageal cancers, pure esophageal NENs were diagnosed in 43 cases. The mean patient age was 55.8 years. The male : female ratio was 1.5 : 1. 81.4% of the tumors were located in the lower third of the esophagus and gastroesophageal junction. Neuroendocrine carcinomas (NEC; G3) accounted for the vast majority of NENs (83.7%). 53.5% patients were Stage IV and 32.5% were Stage III at presentation. The combined median survival of stages II and III patients was 18.25 months, with treatment. The median survival of treated patients with metastatic disease was 6.5 months. Conclusion. Esophageal NENs most commonly were neuroendocrine carcinomas, presented in metastatic stage and were associated with poor prognosis. Grade 2 (G2) tumors had better outcomes than NEC (G3). In nonmetastatic disease, presence of lymph node metastasis and unresectable disease had poorer outcomes.

show abstract

“…11,12 E-NENs rarely secrete hormones, and their clinical manifestations are similar to those of other types of esophageal cancer. 13 Common symptoms of SCNEC are dysphagia, weight loss, gastroesophageal reflux, and chest pain. The morphological features of small cell carcinoma include positive staining for NEN markers.…”

Section: Esophageal Neuroendocrine Neoplasmsmentioning

confidence: 99%

Progress in the treatment of esophageal neuroendocrine carcinoma

Cai

Cui

2017

Tumour Biol.

View full text Add to dashboard Cite

Esophageal neuroendocrine neoplasms are rare. With the improvement and popularization of diagnostic methods, the morbidity statistics have increased annually in recent years. There are currently no treatment guidelines for esophageal neuroendocrine neoplasms, and surgery is the only cure. This usually involves radical surgery when the tumor is limited to the primary site or when only regional lymph node metastasis occurs. Surgical treatment is key to treating esophageal neuroendocrine neoplasms, but combined treatment with chemotherapy and radiotherapy can significantly improve patient survival. The effect of radiotherapy alone on this disease is poor. However, targeted endocrine therapy can improve endocrine hormone symptoms. The prognosis of patients with esophageal neuroendocrine neoplasms is mainly determined by the pathological stage. With the development of molecular biology techniques, the combination of targeted drugs and traditional chemotherapy is expected to provide novel ideas and directions for the treatment of esophageal neuroendocrine neoplasms in the coming years. In this article, the status of esophageal neuroendocrine tumor treatments was reviewed in detail.

show abstract

Primary Small Cell Carcinoma of The Esophagus – An Eight Year Retrospective Study

Cited by 11 publications

References 13 publications

Treatment Strategies and Prognostic Factors of Limited-Stage Primary Small Cell Carcinoma of the Esophagus

Treatment Strategies and Prognostic Factors of Limited-Stage Primary Small Cell Carcinoma of the Esophagus

Clinicopathological Profile of Pure Neuroendocrine Neoplasms of the Esophagus: A South Indian Center Experience

Progress in the treatment of esophageal neuroendocrine carcinoma

Contact Info

Product

Resources

About